ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 229

Divergent Measures of Lupus Disease Damage and Severity Among Asians in an Ethnically Diverse Cohort

Laura Trupin1, Patricia P. Katz2, Cristina Lanata2, Lindsey A. Criswell2, Charles G. Helmick3, Maria Dall'Era2 and Jinoos Yazdany1, 1Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, 2Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 3Centers for Disease Control and Prevention, Atlanta, GA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Outcome measures, race/ethnicity and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Healthcare Disparities in Rheumatology Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is not well characterized among Asian Americans, particularly among subgroups of Asians. We aim to compare measures of disease status, including severity, damage, activity, and physical functioning, by race/ethnicity in a diverse SLE cohort.

Methods: Data were derived from the California Lupus Epidemiology Study (CLUES), a population based, multi-ethnic cohort of SLE patients in the San Francisco area begun in 2015. SLE was defined according to the 1997 ACR criteria. At baseline, participants had a physician exam that included the SELENA- SLE Disease Activity Index (SLEDAI) and SLICC/ACR Damage Index (SDI). The Lupus Severity Index (LSI) was computed based on the ACR criteria confirmed at the study visit. The LSI assigns a weighted value to each criterion and is scaled 0-10; it has been shown to correlate with disease activity and mortality. Patients completed the SF-36 Physical Functioning (PF) subscale; this scale has a potential range of 0-100, with higher values indicating better function. They also provided self-identified race/ethnicity and details of Asian origin. We compared SLE status measures by race/ethnicity and within subgroups of Asian origin, in regression models controlling for age, disease duration, income < 125% of the federal poverty limit, and gender. Tukey post hoc tests were used to compare the outcomes among Asian subgroups.

Results: Among 283 patients, 30% were white, 20% Latino, 11% African American, and 39% Asians. The 102 Asian Americans included 62 Chinese, 23 Filipino and 17 from all other subgroups. Nearly 90% of the cohort were women, with mean age 45±14 and mean disease duration of 16±10 years. Just over half the cohort had some damage (SDI> 0) at baseline. Overall means and distributions of the status measures are shown in the table, along with results from the regression models. Asian Americans in all subgroups had significantly higher LSI scores than whites, as did Latinos and African Americans. However, Asians did not differ from whites in SLICC, SLEDAI or SF-36 PF. Comparing outcomes among the Asian subgroups, the only significant differences were in the SF-36 PF scores, for which Chinese patients had less impairment (mean 48.0) compared to Filipinos (mean 42.1, p=0.02) or other Asians (mean 42.3, p=0.04).

Conclusion: In this multi-ethnic cohort, Asians had high disease severity, similar to African Americans and Latinos, but accumulated significantly less damage than these other racial/ethnic groups over time.  The social, environmental, biological or health factors leading to this paradox among Asians requires further investigation. With the exception of physical functioning, there were few differences between the Asian subgroups, but this analysis was limited by small sample size and should be further explored as the cohort expands.

 

Table. SLE Disease Status Measures by Race/Ethnicity

Lupus Severity Index

SLICC Damage Index

SELENA-SLEDAI

SF36 Physical Functioning

unadjusted mean±sd (range)

Total (n=238)

6.8 ± 1.6 (3.4-9.5)

1.2 ± 1.6 (0-7)

2.8 ± 2.9 (0-16)

44.1± 11.9 (15-57)

Race/ethnicity

adjusted mean (95% confidence interval)*

   Asian

7.1 (6.8-7.4)**

1.2 (0.9-1.5)

2.8 (2.2-3.3)

46.3 (44.1-48.4)

   African American

7.1 (6.6-7.6)**

1.8 (1.2-2.3)**

2.5 (1.5-3.5)

38.2 (34.3-42.1)**

   Hispanic

7.2 (6.9-7.6)**

1.3 (1.0-1.7)

3.2 (2.5-3.9)

42.0 (39.4-44.7)

   White

6.2 (5.9-6.5)

0.8 (0.5-1.2)

2.7 (2.1-3.3)

45.4 (43.0-47.8)

 p-value

(diff by race/ethnicity)

   <0.001

   0.02

   0.67

   0.001

 * Adjusted for age, gender, disease duration, poverty level income (<125% federal poverty limit).

** Results significantly different from Whites for indicated measure.

 


Disclosure: L. Trupin, None; P. P. Katz, Bristol-Myers Squibb, 2; C. Lanata, None; L. A. Criswell, None; C. G. Helmick, None; M. Dall'Era, None; J. Yazdany, None.

To cite this abstract in AMA style:

Trupin L, Katz PP, Lanata C, Criswell LA, Helmick CG, Dall'Era M, Yazdany J. Divergent Measures of Lupus Disease Damage and Severity Among Asians in an Ethnically Diverse Cohort [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/divergent-measures-of-lupus-disease-damage-and-severity-among-asians-in-an-ethnically-diverse-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/divergent-measures-of-lupus-disease-damage-and-severity-among-asians-in-an-ethnically-diverse-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology